CareDx, Inc. is a precision medicine company dedicated to improving the care and outcomes of transplant patients through advanced diagnostic testing and monitoring solutions. The company specializes in noninvasive molecular assays that assess the risk of organ rejection and infection in recipients of heart, kidney, lung and other solid organ transplants. Headquartered in Brisbane, California, CareDx operates a network of CLIA‐certified laboratories and leverages a team of scientists, clinicians and regulatory experts to deliver actionable insights to transplant centers and healthcare providers.
At the core of CareDx’s offering is a suite of proprietary tests designed to guide post‐transplant management. The AlloMap heart gene expression test helps physicians identify patients at low risk of rejection, while AlloSure donor-derived cell-free DNA assays enable early detection of immune responses in heart, kidney and lung allografts. The company also markets AlloSeq next-generation sequencing products and a panel of infectious disease assays that screen transplant recipients for a range of viral, bacterial and fungal pathogens. Complementing these laboratory services, CareDx provides secure digital reporting platforms and patient support programs, including at-home blood collection kits and educational resources.
CareDx’s diagnostics are available in the United States, Europe and the Asia-Pacific region through a combination of direct laboratory operations and strategic partnerships with hospitals, research institutions and commercial laboratories. International expansion is supported by facilities in Marlborough, Massachusetts and Leiden, the Netherlands, where regional teams oversee logistics, regulatory compliance and customer service. The company also collaborates with academic and clinical investigators to generate real-world evidence and refine its testing algorithms.
Founded in 2014 as a spin-off from Viracor-IBT Group, CareDx completed its initial public offering on the NASDAQ in 2017 under the ticker CDNA. Since then, the company has broadened its product pipeline through targeted R&D efforts and acquisitions, including the addition of digital pathology and transplant immunity platforms. CareDx is led by President and Chief Executive Officer Richard Marsh, whose background in diagnostics and life sciences has guided the company’s strategy to advance precision transplant care worldwide.
AI Generated. May Contain Errors.
